Company Long-Term Loans and Borrowings: Roivant Sciences Ltd (ROIV)

Public company logo of Roivant (ROIV)

Significant cash reserves following asset divestitures and share buybacks established the foundation for Roivant Sciences Ltd. (ROIV). Currently, the company's long-term debt levels reflect current capital dynamics, with the parameter stabilizing at 0.08. Looking ahead, growth will be driven by the commercialization of new autoimmune disease medications and the flexible management of subsidiaries to minimize risks during drug development.

ROIV Roivant Sciences Ltd. Company Long-Term Debts (07/04/2022 - 10/31/2026)

Roivant Sciences Ltd (ROIV) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price roivant.com|ROIV - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Roivant Sciences|ROIV - Total Company Value
- book capitalization information:
Accounting Value per Share Roivant Sciences|ROIV - Book Capitalization|Market Capitalization to Book Value Ratio roivant.com|ROIV - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Roivant Sciences Ltd.|ROIV - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Roivant Corp|ROIV - Company Debts|Debts to Book Value Roivant Sciences|ROIV - Company Long-Term Debt|Company Short-Term Debt Roivant Sciences|Immediate Liquidity Ratio roivant.com
- earnings and multiples data:
ROIV - Net Profit
Analysis of all company metrics:Roivant Sciences Ltd.
Brand item of Roivant Corp

Assessing the long-term sustainability of Roivant Sciences Ltd. (ROIV) requires an analysis of its capital structure through the lens of debt load. The dynamics of the company's long-term borrowings reflect the volume of obligations with maturities exceeding one year, excluding quarterly reporting lags. A decrease in this metric confirms solvency, whereas growth indicates expansion. For an innovative holding company, such resources serve as fuel for the monetization of promising medical developments.

Competitors of Roivant Sciences Ltd. (ROIV)

Company Long-Term Debts lilly.com LLY|ABBV - Company Long-Term Debt|Company Long-Term Loans and Borrowings AZN (AstraZeneca Plc)|Novartis Inc. (NVS) - Company Long-Term Debt|Company Long-Term Liabilities MSD|NVO (Novo Nordisk A/S) - Company Long-Term Debts|Company Long-Term Debts amgen.com|Company Long-Term Liabilities PFE (Pfizer)|SNY (Sanofi SA) - Company Long-Term Loans and Borrowings|Company Long-Term Debts BMY (BMS)|Company Long-Term Loans and Borrowings GSK|TAK - Company Long-Term Debt|Long-Term Debt Teva Pharmaceutical Industries Limited|Dr. Reddy's (RDY) - Company Long-Term Debt|VTRS (Viatris Inc) - Company Long-Term Debt|ZLAB (Zai Lab Ltd.) - Company Long-Term Debts|Company Long-Term Indebtedness BHC (Bausch Health Corp)|Company Long-Term Debts COSM